British drugmaker AstraZeneca has cut about 600 jobs from its US sales teams, according to media reports, in the first visible step of a three-year restructuring plan aimed at saving $1.5 billion a year.
Key Points
- AstraZeneca job cuts — Bloomberg News and Reuters reported on 13 November that the company reduced roughly 600 US sales positions in its respiratory and immunology commercial teams.
- The company also scaled back its partnership with contract sales firm Syneos Health, though some affected employees are expected to be reassigned internally.
- The cuts form part of a three-year restructuring plan targeting $1.5 billion in annual savings by 2029, with the money redirected toward pipeline growth.
- AstraZeneca declined to comment on the reports, and the company says it still aims to reach $80 billion in annual revenue by 2030.

The reductions fall on the commercial teams behind AstraZeneca’s respiratory and immunology portfolio, which generated $2.5 billion — about 16% of third-quarter revenue. Within that business, asthma inhalers have struggled: Breztri’s US third-quarter sales rose just 2% year over year to $170 million, while Airsupra fell 3% to $43 million.
The overhaul comes as AstraZeneca redirects capital toward its drug pipeline while reassuring investors it can reach $80 billion in annual revenue by 2030, despite upcoming patent expirations and recent clinical setbacks. The company announced the broader restructuring alongside third-quarter results at the end of October, when it said it would spend about $2 billion on the programme to generate $1.5 billion in annual benefits.
A wider pattern in pharma
AstraZeneca is not alone in tightening its belt. Drugmakers across the industry are under pressure from patent cliffs, pricing scrutiny and the high cost of developing new medicines, and several have cut commercial roles while protecting research spending. For AstraZeneca, the logic is to spend less on selling today’s drugs and more on developing tomorrow’s — a trade that makes sense on a spreadsheet but is painful for the sales representatives whose roles are being eliminated or reshaped.
Some of those affected are expected to be reassigned internally rather than leaving the company, and the reported figure is a headcount of positions affected, not a confirmed number of departures. Even so, 600 roles is a significant cut in a single country’s commercial operation, and it signals how seriously the company is taking its savings target.
What comes next
Investors will watch whether the savings actually materialise and whether the pipeline delivers the growth AstraZeneca is promising. The company’s third-quarter profit beat expectations, helped by blockbuster cancer drugs, which gives it room to argue the restructuring is about focus rather than distress. For the affected US employees, the coming weeks will bring clarity on which roles move, which disappear, and what support the company offers in the meantime.
For background on another major restructuring, see our report on Volkswagen announcing a major restructuring involving 50,000 job cuts, and on Wall Street rebounding as a strong jobs report fuels December Fed rate hike bets. More in our Business section.
Sources: Decode News AI, “AstraZeneca Cuts About 600 US Sales Jobs Under $1.5 Billion Savings Plan” (reporting Bloomberg News and Reuters, 13 November 2026) (https://decodenewsai.us/en/posts/2026-11-14-astrazeneca-us-layoffs-cost-savings-pharmaceutical-0b4a77).
